Practice changers for BPT trainees
74 papers from the last 12 months that change - or confirm - how physicians practise. New evidence is exactly the kind of thing that turns up in exam questions and on ward rounds.
Each paper is tagged by what it does to practice: adopt something new, stop something, refine how it is done, or confirm current practice. In BPTBuddy, every one is set against what the guidelines said before, and linked to the notes it updates.
Cardiology
- SINGLE-AF - Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk (NEJM, Aug 2026) · Adopt
- PVI-SHAM-AF - Catheter ablation for symptomatic atrial fibrillation (PVI-SHAM-AF): a randomised, double-blind, sham-controlled, multicentre trial (Lancet, Aug 2026) · Refine
- ABYSS + SMART-DECISION - Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data (Lancet, Aug 2026) · Stop doing
- PRESC1SE-MI - Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial (Lancet, Aug 2026) · Confirms
- OPTIMA-AF - 1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial (Lancet, Jul 2026) · Refine
- Efficacy of dual antiplatelet therapy for three months versus 12 months after coronary artery bypass grafting: multicentre, double blinded, randomised controlled trial (BMJ, May 2026) · Refine
- CHAMPION-AF - Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation (NEJM, Mar 2026) · Refine
- CLOSURE-AF - Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation (NEJM, Mar 2026) · Stop doing
- Ez-PAVE - Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease (NEJM, Mar 2026) · Adopt
- RECOVERY (10-year) - Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years (NEJM, Mar 2026) · Adopt
- CTT (statin adverse effects) - Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials (Lancet, Feb 2026) · Refine
- Vutrisiran for transthyretin amyloidosis (Aust Prescr, Feb 2026) · Adopt
- OCEAN - Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation (NEJM, Nov 2025) · Refine
- VESALIUS-CV - Evolocumab in Patients without a Previous Myocardial Infarction or Stroke (NEJM, Nov 2025) · Adopt
- CORE and CORE2 - Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk (NEJM, Nov 2025) · Emerging
- ADAPT AF-DES - Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents (NEJM, Nov 2025) · Confirms
- CRTC - Complete versus culprit lesion-only revascularisation for acute myocardial infarction (Complete Revascularisation Trialists' Collaboration): an individual patient data meta-analysis of randomised trials (Lancet, Nov 2025) · Confirms
- RAFF4 - Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial (BMJ, Nov 2025) · Emerging
- iMODERN - Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction (NEJM, Oct 2025) · Confirms
Dermatology
- Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies (NEJM, May 2026) · Stop doing
- Oral ivermectin versus 5% permethrin cream to treat children and adults with classic scabies: multicentre, assessor blinded, cluster randomised clinical trial (BMJ, Jan 2026) · Confirms
Endocrinology
- Calcium, vitamin D, or combined supplementation to prevent fractures and falls: systematic review and meta-analysis (BMJ, May 2026) · Stop doing
- SURPASS-CVOT - Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (NEJM, Dec 2025) · Confirms
Gastroenterology
- EPoS II - Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal (NEJM, Sep 2026) · Refine
- RESOLVE - 8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India (Lancet, Sep 2026) · Refine
- Elafibranor for primary biliary cholangitis (Aust Prescr, Aug 2026) · Adopt
- Bulevirtide for hepatitis D infection (Aust Prescr, Jun 2026) · Adopt
- B-Well 1 and 2 - Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection (NEJM, May 2026) · Emerging
- NordICC (13-year) - Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial (Lancet, May 2026) · Refine
General Medicine
- SODa-BIC - Sodium Bicarbonate for Critically Ill Adults with Metabolic Acidosis and Shock (NEJM, Jun 2026) · Stop doing
- LOGICAL - Conservative Oxygen for Unresponsive Patients after Cardiac Arrest (NEJM, Jun 2026) · Confirms
- RSI - Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults (NEJM, Dec 2025) · Refine
- SuDDICU - Selective Decontamination of the Digestive Tract during Ventilation in the ICU (NEJM, Oct 2025) · Stop doing
Geriatric Medicine
- STAREE - Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults (NEJM, Aug 2026) · Refine
Haematology
- PARADIGM - Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia (NEJM, Sep 2026) · Emerging
- ITACS - Intravenous iron to treat anaemia before cardiac surgery (ITACS): international, double blind, placebo controlled randomised trial (BMJ, Aug 2026) · Adopt
- COBRRA - Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism (NEJM, Mar 2026) · Adopt
- CLL17 - Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia (NEJM, Dec 2025) · Confirms
Immunology and Allergy
- Adrenaline (epinephrine) nasal spray for severe allergic reactions (Aust Prescr, Apr 2026) · Adopt
Infectious Diseases
- GoGoVax - Meningococcal B Vaccine to Prevent Neisseria gonorrhoeae Infection (NEJM, Jul 2026) · Stop doing
- ASTARTE - Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial (Lancet, Jul 2026) · Emerging
- BEAT Tuberculosis - A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis (NEJM, Jun 2026) · Confirms
- SNAP (cefazolin domain) - Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia (NEJM, Jun 2026) · Adopt
- SNAP (PSSA domain) - Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial (Lancet, Jun 2026) · Adopt
- SCOUT - Clinical and bacteriological effectiveness of three different short-course antibiotic regimens and single-dose fosfomycin for uncomplicated lower urinary tract infections in women (SCOUT): a pragmatic, multicentre, open-label, randomised clinical trial (Lancet, Apr 2026) · Confirms
- ESCUDDO - Noninferiority of One HPV Vaccine Dose to Two Doses (NEJM, Dec 2025) · Confirms
- Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial (Lancet, Dec 2025) · Emerging
- SONIA - A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia (NEJM, Oct 2025) · Refine
- CloCeBa - Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial (Lancet, Oct 2025) · Confirms
Nephrology
- FIND-CKD - Finerenone in Persons with Chronic Kidney Disease without Diabetes (NEJM, Jun 2026) · Emerging
- MAJESTY - Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy (NEJM, Jun 2026) · Emerging
- BPLTTC (CKD) - Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis (Lancet, Apr 2026) · Confirms
- PISCES - Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis (NEJM, Nov 2025) · Adopt
- BigpAK-2 - A preventive care strategy to reduce moderate or severe acute kidney injury after major surgery (BigpAK-2); a multinational, randomised clinical trial (Lancet, Nov 2025) · Adopt
Neurology
- Donanemab for early Alzheimer disease (Aust Prescr, Aug 2026) · Emerging
- OVERLORD-MS - Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis (NEJM, Jul 2026) · Adopt
- Antithrombotic treatment for migraine in patients with patent foramen ovale: multicentre, randomised, active controlled, open label trial (BMJ, Jul 2026) · Emerging
- ORIENTAL-MeVO - Endovascular Treatment of Medium-Vessel-Occlusion Strokes (NEJM, May 2026) · Refine
- ATLAS - Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data meta-analysis with central imaging adjudication (Lancet, May 2026) · Confirms
- TRIDENT - Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage (NEJM, Apr 2026) · Adopt
- OCEANIC-STROKE - Asundexian for Secondary Stroke Prevention (NEJM, Apr 2026) · Emerging
- TRACE-5 - Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial (Lancet, Feb 2026) · Emerging
- FASTEST - Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial (Lancet, Feb 2026) · Stop doing
- TenCRAOS - A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion (NEJM, Jan 2026) · Stop doing
- CREST-2 - Medical Management and Revascularization for Asymptomatic Carotid Stenosis (NEJM, Nov 2025) · Refine
Oncology
- ATOMIC - Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer (NEJM, Mar 2026) · Adopt
- PATCH / STAMPEDE - Transdermal Estradiol Patches in Locally Advanced Prostate Cancer (NEJM, Mar 2026) · Refine
- ERSPC (23-year) - European Study of Prostate Cancer Screening - 23-Year Follow-up (NEJM, Oct 2025) · Confirms
Pharmacology, Toxicology and Addiction Medicine
- Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial (Lancet, May 2026) · Emerging
- NACSTOP 2 - Early Cessation of Acetylcysteine Treatment After Paracetamol Overdose (NACSTOP 2): A Non-Inferiority Randomised Controlled Trial (MJA, Jan 2026) · Adopt
Respiratory
- TETON-2 - Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis (NEJM, Mar 2026) · Emerging
- HI-PEITHO - Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism (NEJM, Mar 2026) · Refine
Rheumatology
- REPLENISH - Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica (NEJM, Jun 2026) · Emerging
- ALLEGORY - Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus (NEJM, Mar 2026) · Emerging
Preparing for the written exam? Read our guide to the BPT written exam.
Study for the BPT exam with BPTBuddy
Notes across the curriculum, the facts past papers test, flashcards and the year's practice changers - one search away, from your first term of BPT to the written exam.